Previous 10 | Next 10 |
2023-11-22 16:27:08 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic For fu...
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis PR Newswire – Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond – – Third U.S. Pa...
--News Direct-- Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update. Dr Vitt starts by describing the quarter as a "very eventful and positive quarter for us, dominated by a k...
2023-11-14 10:53:04 ET Immunic, Inc. (IMUX) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Dr. Daniel Vitt - CEO and President Glenn Whaley - CFO Conference Call Participants...
2023-11-14 06:30:08 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic For fu...
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire – Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overal...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
2023-11-13 13:12:56 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic Histor...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK , Nov. 7, 2023 /PRNewswire/ -- Immu...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
--News Direct-- Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. Muehler explained that IBD encompasses Crohn's disease and ulcerative colitis, characterised ...
--News Direct-- Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease and the company’s developments in treating it. Kohlhof explai...
--News Direct-- Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseas...